HLA alleles and hypersensitivity to carbamazepine: An updated systematic review with meta-analysis

Pharmacogenetics and Genomics

Volumn 24, Issue 2, 2014, Pages 94-112

  Grover, Sandeep ^a   Kukreti, Ritushree ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

adverse drug reactions; antiepileptic drugs; genetic variants; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

CARBAMAZEPINE;

ARTICLE; DRUG HYPERSENSITIVITY; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; HLA SYSTEM; HUMAN; INFORMATION RETRIEVAL; MACULOPAPULAR RASH; MARKER GENE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RISK ASSESSMENT; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TOXIC EPIDERMAL NECROLYSIS;

ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMAZEPINE; DRUG HYPERSENSITIVITY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84895040779     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000021     Document Type: Article

References (62)

1. Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Ketter TA, Kalali AH. Group SPDS. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: A multicenter, randomized, double-blind, placebocontrolled trial. J Clin Psychiatry 2005; 66:323-330
2. Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev 2011 Article No. CD005451
3. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272-1285
4. Yarbrough DR III. Experience with toxic epidermal necrolysis treated in a burn center. J Burn Care Rehabil 1996; 17:30-33
5. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204:503-512
6. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008; 58: 33-40
7. Pichler WJ, Naisbitt DJ, Park BK. Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol 2011; 127:S74-S81
8. Hakimian S, Miller JW. The genetics of antiepileptic drug-induced skin reactions. Clin Pharmacol Ther 2011; 89:908-910
9. Striano P, Zara F. Epilepsy: HLA alleles linked to carbamazepine hypersensitivity. Nat Rev Neurol 2011; 7:365-366
10. Wu XT, Hu FY, An DM, Yan B, Jiang X, Kwan P, et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B&z.ast;1502 allele among patients in central China. Epilepsy Behav 2010; 19:405-408
11. Zhang Y, Wang J, Zhao LM, Peng W, Shen GQ, Xue L, et al. Strong association between HLA-B&z.ast;1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol 2011; 67:885-887
12. Wang Q, Zhou JQ, Zhou LM, Chen ZY, Fang ZY, Chen SD, et al. Association between HLA-B&z.ast;1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure 2011; 20:446-448
13. Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B&z.ast;1502 allele in Thai population. Epilepsia 2008; 49:2087-2091
14. Shi YW, Min FL, Qin B, Zou X, Liu XR, Gao MM, et al. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: Genetic markers besides B&z.ast;1502? Basic Clin Pharmacol Toxicol 2012; 111:58-64
15. Then SM, Rani ZZ, Raymond AA, Ratnaningrum S, Jamal R. Frequency of the HLA-B&z.ast;1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol 2011; 29:290-293
16. Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, et al. Association of HLA-B&z.ast;1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009; 75:579-582
17. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 2004; 428:486
18. TassaneeyakulW, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH, et al. Association between HLA-B&z.ast;1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010; 51:926-930
19. Kulkantrakorn K, Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Prabmechai N, Vannaprasaht S, et al. HLA-B&z.ast;1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Pract 2012; 12: 202-208
20. Cheung YK, Cheng SH, Chan EJ, Lo SV, Ng MH, Kwan P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 2013; 54:1307-1314
21. Amstutz U, Ross CJ, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther 2013; 94:142-149
22. Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B&z.ast;1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9:1543-1546
23. Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, et al. Genome-wide association study identifies HLA-A&z.ast;3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20:1034-1041
24. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, et al. HLA-A&z.ast;3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134-1143
25. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16:297-306
26. Kim SH, Lee KW, Song WJ, Jee YK, Lee SM, Kang HR, et al. Adverse Drug Reaction Research Group in Korea. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 2011; 97:190-197
27. Locharernkul C, Shotelersuk V, Hirankarn N. Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions. J Clin Neurosci 2011; 18:1289-1294
28. Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: A systematic review. Clin Pharmacol Ther 2012; 92:757-765
29. Grover S, Kukreti R. HLA allelic variants and carbamazepine induced hypersensitivity. Clin Pharmacol Ther 2013; 93:386-387
30. Lewis S, Clarke M. Forest plots: Trying to see the wood and the trees. BMJ 2001; 322:1479-1480
31. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188
33. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10:101-129
34. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005; 28:123-137
35. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127:820-826
36. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634
37. Wu Y, Wang XQ, Gan ZJ, Fan M. HLA-B&z.ast;1502 allele screening: Determination of carbamazepine-induced cutaneous reactions. Epilepsia 2012; 53:929-930
38. Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol 2012; 39:594-601
39. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7:813-818
40. Chang CC, Too CL, Murad S, Hussein SH. Association of HLA-B&z.ast;1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol 2011; 50:221-224
41. Lin YT, Chang YC, Hui RC, Yang CH, Ho HC, Hung SI, Chung WH. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol 2012; 27:356-364
42. Li LJ, Hu FY, Wu XT, An DM, Yan B, Zhou D. Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese. Epilepsy Res 2013; 106:296-300
43. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al. Carbamazepineinduced toxic effects and HLA-B&z.ast;1502 screening in Taiwan. N Engl J Med 2011; 364:1126-1133
44. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18:99-107
45. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, et al. A marker for Stevens-Johnson syndromey: Ethnicity matters. Pharmacogenomics J 2006; 6:265-268
46. Ikeda H, Takahashi Y, Yamazaki E, Fujiwara T, Kaniwa N, Saito Y, et al. HL A class I markers in Japanese patients with carbamazepineinduced cutaneous adverse reactions. Epilepsia 2010; 51: 297-300
47. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. JSAR research group. HLA-B&z.ast;1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010; 51:2461-2465
48. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. JSAR research group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9:1617-1622
49. Kashiwagi M, Aihara M, Takahashi Y, Yamazaki E, Yamane Y, Song Y, et al. Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients. J Dermatol 2008; 35:683-685
50. Kano Y, Hirahara K, Asano Y, Shiohara T. HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions. Acta Derm Venereol 2008; 88:616-618
51. Sun D, Shi YW, Liu ZS, Liao WP, Wang FL, Wu GF, et al. Hypersensitivity syndrome reactions to antiepileptic drugs, clinical characteristic and association with HLA-B&z.ast;1502. Zhonghua Yi Xue Za Zhi 2010; 90: 2763-2766
52. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH. Association between HLA-B&z.ast;1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48:1015-1018
53. Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 2001; 56:890-896
54. Neuman MG, Cohen L, Nanau RM, Hwang PA. Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Transl Res 2012; 159:397-406
55. Wu X, Graf E, Schmitt FC, Kurlemann G, Kunz WS, Heers M, et al. The association between AED-induced cutaneous adverse drug reactions and the HLA-A, -B, and -DRB1 alleles among Caucasian patients: A pilot multicenter study. Z Epileptol 2012; 25:289-292
56. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B&z.ast;5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102:4134-4139
57. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-1122
58. Wang J, Zhang J,Wu X, Yu P, Hong Z. HLA-B&z.ast;1502 allele is associated with a cross-reactivity pattern of cutaneous adverse reactions to antiepileptic drugs. J Int Med Res 2012; 40:377-382
59. Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010; 11:349-356
60. An DM, Wu XT, Hu FY, Yan B, Stefan H, Zhou D. Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B&z.ast;1502 in a Han Chinese population. Epilepsy Res 2010; 92:226-230
61. Shi YW, Min FL, Liu XR, Zan LX, Gao MM, Yu MJ, Liao WP. Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. Basic Clin Pharmacol Toxicol 2011; 109:42-46
62. Trachtenberg E, Vinson M, Hayes E, Hsu YM, Houtchens K, Erlich H, et al. HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China. Tissue Antigens 2007; 70: 455-463